Clinical Trial Update: A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating CPI-0610 with and without ruxolitinib in patients with hematologic and myeloproliferative malignancies. The study status is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Essential Thrombocythemia
• Leukemia
• Myelodysplastic Myeloproliferative Neoplasms
• Myelodysplastic Syndromes
• Myelofibrosis
• Myeloproliferative Neoplasms

Drugs mentioned

• CPI-0610 (CPI-0610)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Constellation Pharmaceuticals | Conditions: Myelofibrosis, Leukemia, Myelocytic, Acute | Phase 1, Phase 2 | Status: COMPLETED